Medicxi
VC Fund
London, United Kingdom
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 55%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Medicxi invests in
Stages Medicxi invests in
Countries Medicxi invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Investment Focus
Industry
- Biotechnology 43 (69%)
- Health Care 20 (32%)
- Therapeutics 19 (31%)
- Pharmaceutical 18 (29%)
- Medical 11 (18%)
Stage
- Series A 20 (32%)
- Series B 14 (23%)
- Seed 7 (11%)
- Series C 3 (5%)
- Series D 3 (5%)
Country
- United States 19 (31%)
- United Kingdom 14 (23%)
- The Netherlands 3 (5%)
- China 2 (3%)
- France 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Giovanni Pericolini
Finance Director & CFO
|
Finance Director & CFO | Total investments: 0 | Find email | |
Kevin Johnson
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 6 | Find email | |
Mark Boer
Member of the Board of Advisors
|
Member of the Board of Advisors | Total investments: 0 | Find email | |
Michele Bauer
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 3 | Find email | |
Trevor Baglin
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | ||
| Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments against age-old threats to human health: high-consequence viral pathogens. | $75M / Series B / Feb 19, 2026 | ||
| D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $108M / Series B / Dec 09, 2025 | ||
| We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M / Series D / May 06, 2025 | ||
| Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $110M / Series B / Mar 17, 2025 | ||
| RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development. | $150M / Post-IPO Equity / Dec 23, 2024 | ||
| Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M / Series A / Dec 19, 2024 | ||
| Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | Seed / Oct 28, 2024 | ||
| Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M / Series B / Sep 23, 2024 | ||
| Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs. | $41M / Series A / Jun 01, 2024 | ||
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Medicxi invest in?
Medicxi invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 62 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Medicxi?
Public channels for Medicxi include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Medicxi?
The team at Medicxi includes Giovanni Pericolini (Finance Director & CFO), Kevin Johnson (Co-Founder & Partner) and Mark Boer (Member of the Board of Advisors), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
